Kymera Therapeutics (NASDAQ:KYMR) Issues Earnings Results, Beats Expectations By $0.04 EPS

Kymera Therapeutics (NASDAQ:KYMR) posted its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04, Briefing.com reports. The firm had revenue of $10.30 million for the quarter, compared to analyst estimates of $14.24 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The company’s revenue was up 8.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.70) EPS.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $1.10 on Friday, hitting $37.40. The stock had a trading volume of 529,366 shares, compared to its average volume of 717,655. The stock has a 50 day moving average of $38.61 and a 200 day moving average of $29.16. Kymera Therapeutics has a twelve month low of $9.60 and a twelve month high of $45.31. The firm has a market capitalization of $2.29 billion, a P/E ratio of -14.59 and a beta of 2.31.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 71,764 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the completion of the transaction, the director now directly owns 806,697 shares in the company, valued at approximately $32,638,960.62. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Bruce Booth sold 71,764 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $40.46, for a total transaction of $2,903,571.44. Following the completion of the transaction, the director now directly owns 806,697 shares in the company, valued at $32,638,960.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $42.85, for a total value of $1,812,640.70. Following the completion of the sale, the insider now owns 4,925,812 shares in the company, valued at $211,071,044.20. The disclosure for this sale can be found here. Insiders have sold 474,051 shares of company stock valued at $19,624,211 in the last ninety days. 16.67% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on Kymera Therapeutics from $34.00 to $47.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Piper Sandler increased their price objective on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Oppenheimer dropped their target price on shares of Kymera Therapeutics from $53.00 to $52.00 and set an “outperform” rating for the company in a research report on Friday. Wolfe Research assumed coverage on shares of Kymera Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating for the company. Finally, Truist Financial lifted their price objective on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.